CRISPR THERAPEUTICS AG (CRSP)
Health Care · Gene-editing therapeutics / CRISPR-based medicines · NASDAQ
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and beta thalassemia, plus a pipeline of in vivo and cell therapy programs.
What CRISPR THERAPEUTICS AG does
CRISPR Therapeutics is a biopharmaceutical company focused on developing CRISPR-based gene-editing therapeutics for serious human diseases. The company's flagship product CASGEVY (exagamglogene autotemcel), developed in collaboration with Vertex Pharmaceuticals, became the first approved CRISPR-based therapy in the world, approved for treating eligible patients with severe sickle cell disease and transfusion-dependent beta thalassemia. Beyond hemoglobinopathies, CRISPR is advancing a portfolio spanning in vivo liver editing programs, next-generation CAR T cell therapies for autoimmune and oncology indications, and regenerative medicine programs including a beta cell replacement candidate for Type 1 diabetes.
Themes: ["Gene editing / CRISPR therapeutics","Hemoglobinopathies (sickle cell disease, beta thalassemia)","In vivo liver editing","CAR T cell therapy","Regenerative medicine / beta cell replacement","Lipid nanoparticle (LNP) delivery","Gene therapy"]
Fundamentals
- Price$56.34 as of 2026-07-09 close
- Market cap$5.5B as of 2026-07-10
- 1-year return-6.2% as of 2026-07-09 close
- Net margin-13856.5% as of 2026-07-10
- ROE-30.9% as of 2026-07-10
- Debt / equity0.32 as of 2026-07-10
- Revenue growth (YoY)-89.1% as of 2026-07-10
- Revenue CAGR (3y)+43.1% SEC XBRL
- Beta1.76 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.